Todd Christopher Longsworth, General Counsel at NovoCure Ltd (NVCR), sold 107,328 shares at $171.32 ($18.5M) on 2021-01-15, disclosed to the SEC on 2021-01-19.
Seasonal sale ($18.5M) by General Counsel — this insider has traded NVCR in January in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $167.76 | 2,499 | $419K | 2.3% |
| 2 | $167.76 | 2,499 | $419K | 2.3% |
| 3 | $167.77 | 3,500 | $587K | 3.2% |
| 4 | $168.80 | 800 | $135K | 0.7% |
| 5 | $169.19 | 1,800 | $305K | 1.6% |
| 6 | $169.76 | 2,148 |
| $365K |
| 2.0% |
| 7 | $169.76 | 2,148 | $365K | 2.0% |
| 8 | $169.93 | 2,542 | $432K | 2.3% |
| 9 | $169.93 | 2,542 | $432K | 2.3% |
| 10 | $171.18 | 2,761 | $473K | 2.6% |
| 11 | $171.18 | 2,761 | $473K | 2.6% |
| 12 | $171.32 | 4,826 | $827K | 4.5% |
| 13 | $171.32 | 4,826 | $827K | 4.5% |
| 14 | $171.86 | 10,110 | $1.7M | 9.4% |
| 15 | $171.86 | 10,110 | $1.7M | 9.4% |
| 16 | $171.90 | 11,985 | $2.1M | 11.1% |
| 17 | $171.90 | 11,985 | $2.1M | 11.1% |
| 18 | $172.95 | 1,300 | $225K | 1.2% |
| 19 | $172.95 | 1,300 | $225K | 1.2% |
| 20 | $173.10 | 1,700 | $294K | 1.6% |
| 21 | $173.88 | 1,600 | $278K | 1.5% |
| 22 | $174.06 | 2,502 | $435K | 2.4% |
| 23 | $174.06 | 2,502 | $435K | 2.4% |
| 24 | $175.14 | 1,700 | $298K | 1.6% |
| 25 | $175.28 | 2,200 | $386K | 2.1% |
| 26 | $175.98 | 400 | $70K | 0.4% |
| 27 | $176.22 | 400 | $70K | 0.4% |
| 28 | $177.31 | 2,200 | $390K | 2.1% |
| 29 | $177.33 | 2,841 | $504K | 2.7% |
| 30 | $177.33 | 2,841 | $504K | 2.7% |
| 31 | $178.50 | 900 | $161K | 0.9% |
| 32 | $178.68 | 1,000 | $179K | 1.0% |
| 33 | $179.30 | 1,200 | $215K | 1.2% |
| 34 | $179.37 | 900 | $161K | 0.9% |
| Total | $172.22 avg | 107,328 | $18.5M | 100% |
| Filing → |
| NVCR | SELL | 2021-03-10 | $629K | — | Filing → |
| NVCR | SELL | 2021-03-08 | $848K | — | Filing → |
| NVCR | SELL | 2021-03-04 | $716K | — | Filing → |